Objectives: Prostatodynia (type III–B according to the classification of the National Institute of Diabetes and Digestive and Kidney Diseases) represents a major part of all chronic prostatitis syndromes. Uroflowmetry changes in these patients were rarely described, and discrepancies exist about the prevalence of urodynamic abnormalities. The aim of this study was to describe both qualitative and quantitative flowmetrogram characteristics in these patients.Methods: Two hundred and thirty–eight flowmetrograms from patients diagnosed as having prostatodynia and 71 flowmetrograms from control males with matched age but without lower urinary tract problems were evaluated. Two to three flowmetric analyses were done for each individual, and the best one, i.e., representing the individual’s voiding and no artefact (e.g., wag artefact), was chosen. A minimal voided volume of 150 ml was required to be included. Diagnosis of prostatodynia followed the routine criteria. For all patients the postvoiding residual urine was assessed by ultrasound (Bladder Scan). Qualitative study was done according to a classification using flow–time ratio (TQm/T100×100) and flow ratio (Qave/Qmax×100) for continuous flow. Interrupted flow was classified separately. Descriptive statistical analysis was used.Results: The age range was 18–49 (mean ± SD, 34.2±7.8) years. The symptom duration ranged from 3 to 84 (16.5±27.7) months. Out of 238 patients 196 had uninterrupted flow. Thirty–six patients showed interrupted flow due to external sphincter contraction ≤2 s, and 6 patients showed interrupted flow with abdominal muscle straining. Out of the 196 patients, 73 showed Qmax >15 ml/s, and 67 showed a voided volume <200 ml. For this group the Qmax was 13.3±5.3 ml/s, Qave was 7.6±3.0 ml/s, and the mean postvoiding residual urine was 29.9 (range 0–234) ml. Type I flowmetry pattern was present in 39.7%, type II in 38.7%, type III in 5%, type IV in 16%, and type V in 0.5% of the patients with continuous flow (see Patients and Methods). The control group showed a Qmax of 19.5±3.8 ml/s, a Qave of 11.1±2.6 ml/s, a voided volume of 311.9±106.9 ml, and a postvoiding residual urine of 14.3±29.3 ml/s. Pattern I was seen in 89%, pattern II in 8%, and pattern IV in 3% of the controls.Conclusion: Most patients with prostatodynia had abnormal flowmetry parameters, and different patterns were shown, confirming that many have urinary flow disorders. Flowmetry should be part of the prostatodynia patient diagnostic workup, as this might add to the understanding of patient problems and may help in the selection of more appropriate methods in order to define the pathophysiologic basis of the symptoms and to perform treatment accordingly.

1.
Committee of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Chronic Prostatitis Workshop, Bethesda 1995.
2.
Weidner W, Schiefer HG, Krauss H, Jantos CH, Friedrich HJ, Altmannsberger M: Chronic prostatitis: A thorough search for etiologically involved microorganisms in 1,461 patients. Infection 1991;19(suppl 3):119–125.
3.
Thin RN: The diagnosis of prostatitis: A review. Genitourin Med 1991;67:279–283.
4.
Moon TD: Questionnaire survey of urologists and primary care physicians’ diagnostic and treatment practices for prostatitis. Urology 1997;50:543–547.
5.
Osborn DE, George NJR, Rao PN, Barnard RJ, Reading C, Marklow C, Blacklock NJ: Prostatodynia: Physiological characteristics and rational management with muscle relaxants. Br J Urol 1981;53:621–623.
6.
Barbalias GA, Meares EM Jr, Sant GR: Prostatodynia: Clinical and urodynamic characteristics. J Urol 1983;130:514–517.
7.
Barbalias GA: Prostatodynia or painful male urethral syndrome? Urology 1990;36:146–153.
8.
Neal DE Jr, Moon TD: Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994;43:460– 465.
9.
Ludwig M, Weidner W: Prostatitis and urethritis. Eur Urol 1999;35:5–6 (Curric Urol 2.4:1– 10.
10.
Meares SM, Stamey TA: Bacteriological localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968:492–518.
11.
Ghobish A: Quantitative classification of flowmetrogram patterns. Proc 26th Annu Meet Int Continence Soci. Bologna, Monduzzi, 1996, pp 31–37.
12.
Nickel JC: Prostatitis: Myths and realities. Urology 1998;51:362–366.
13.
Ghobish A: Pattern of presentation and findings in patients with chronic prostatitis/chronic pelvic pain syndrome (abstract 45). 12th Saudi Urology Conf, Taif 1998.
14.
Nickel JC, Costerton JW: Coagulase negative staphylococcus in chronic prostatitis. J Urol 1992;147:398–401.
15.
Segura JW, Opitz JL, Greene IF: Prostatosis, prostatitis, or pelvic floor tension myalgia? J Urol 1979;122:168–169.
16.
Siroky MB, Goldstein I, Krane RJ: Functional voiding disorders in men. J Urol 1981;126: 200–204.
17.
Miller JL, Rothman I, Bavendam TG, Berger RE: Prostatodynia and interstitial cystitis one and the same? Urology 1995;45:587–590.
18.
Ghobish A: Spectrum of cystoscopic and light microscopic changes in patients with persistent cystitis syndrome (abstract 55). 12th Saudi Urology Conf, Taif 1998.
19.
Abrams P, Feneley R, Torrens M: Urodynamics. Berlin, Springer, 1983, pp 28–96.
20.
Blacklock NJ: Urodynamic and psychometric observations and their implications in the management of prostatodynia; in: Weidner W, Brunner H, Krause W, Rothange CF (eds): Therapy of Prostatitis. München, Zuckschwerdt, 1986, vol 11, pp 201–206.
21.
Hellström WJG, Schmidt RA, Lue TF, Tanagho EA: Neuromuscular dysfunction in nonbacterial prostatitis. Urology 1987;30: 183–188.
22.
Anderson JT, Walters S: Urodynamic studies of the lower tract; in Whitfield HN, Hendry WF, Kirby RS, Duckett JW (eds): Textbook of Genitourinary Surgery, ed 2. Oxford, Blackwell, 1998, vol 1, pp 103–115.
23.
Meyhoff HH, Glan DE: Uroflowmetry Methods in Clinical Urodynamics. 1991, vol 1, pp 2–6.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.